Improved understanding of the molecular signatures of NSCLC has led to the development of targeted therapeutics against epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), or anaplastic lymphoma kinase (ALK) alterations which can result in significant response and extended OS. This evidence concerns the gene KRAS and non-small cell lung carcinoma.